Inhibiting EHMT2 in cancer cells, using either pharmacological inhibitors or genetic approaches, enhanced NK cell-mediated killing in several cancer types, including uveal melanoma, triple-negative breast cancer, and pancreatic cancer. This evidence concerns the gene EHMT2 and triple-negative breast carcinoma.